{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T23:35:50Z","timestamp":1780788950276,"version":"3.54.1"},"publisher-location":"Cham","reference-count":88,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319524788","type":"print"},{"value":"9783319524795","type":"electronic"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1007\/978-3-319-52479-5_1","type":"book-chapter","created":{"date-parts":[[2017,3,28]],"date-time":"2017-03-28T11:39:21Z","timestamp":1490701161000},"page":"3-19","source":"Crossref","is-referenced-by-count":9,"title":["Application of Proteomic Techniques for Improved Stratification and Treatment of Schizophrenia Patients"],"prefix":"10.1007","author":[{"given":"Johann","family":"Steiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Guest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Martins-de-Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,29]]},"reference":[{"key":"1_CR1","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","volume":"374","author":"J Os van","year":"2009","unstructured":"van Os J, Kapur S (2009) Schizophrenia. Lancet 374:635\u2013645","journal-title":"Lancet"},{"key":"1_CR2","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). American Psychiatric Publishing, 5th edn (31 May 2013) ISBN-10: 0890425558","DOI":"10.1176\/appi.books.9780890425596"},{"key":"1_CR3","unstructured":"World Health Organization. ICD-10: The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. World Health Organisation (1 Jan 1992). ISBN-10: 9241544228"},{"key":"1_CR4","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1192\/bjp.bp.113.127753","volume":"205","author":"M Penttil\u00e4","year":"2014","unstructured":"Penttil\u00e4 M, J\u00e4\u00e4skel\u00e4inen E, Hirvonen N, Isohanni M, Miettunen J (2014) Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 205:88\u201394","journal-title":"Br J Psychiatry"},{"key":"1_CR5","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s004060070002","volume":"250","author":"A Jablensky","year":"2000","unstructured":"Jablensky A (2000) Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci 250:274\u2013285","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1_CR6","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(13)61611-6","volume":"382","author":"HA Whiteford","year":"2013","unstructured":"Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE et al (2013) Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 382:1575\u20131586","journal-title":"Lancet"},{"key":"1_CR7","doi-asserted-by":"crossref","first-page":"e61718","DOI":"10.1371\/journal.pone.0061718","volume":"8","author":"Y Liu","year":"2013","unstructured":"Liu Y, Dalal K, Stollenwerk B (2013) The association between health system development and the burden of cardiovascular disease: an analysis of WHO country profiles. PLoS One 8:e61718","journal-title":"PLoS One"},{"key":"1_CR8","first-page":"465","volume":"10","author":"MT Tsuang","year":"1975","unstructured":"Tsuang MT (1975) Heterogeneity of schizophrenia. Biol Psychiatry 10:465\u2013474","journal-title":"Biol Psychiatry"},{"key":"1_CR9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0165-0327(98)00032-9","volume":"50","author":"A Gonzalez-Pinto","year":"1998","unstructured":"Gonzalez-Pinto A, Gutierrez M, Mosquera F, Ballesteros J, Lopez P, Ezcurra J et al (1998) First episode in bipolar disorder: misdiagnosis and psychotic symptoms. J Affect Disord 50:41\u201344","journal-title":"J Affect Disord"},{"key":"1_CR10","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1037\/0022-006X.64.6.1120","volume":"64","author":"WC Follette","year":"1996","unstructured":"Follette WC, Houts AC (1996) Models of scientific progress and the role of theory in taxonomy development: a case study of the DSM. J Consult Clin Psychol 64:1120\u20131132","journal-title":"J Consult Clin Psychol"},{"key":"1_CR11","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1365-3024.2009.01131.x","volume":"31","author":"RH Yolken","year":"2009","unstructured":"Yolken RH, Dickerson FB, Fuller Torrey E (2009) Toxoplasma and schizophrenia. Parasite Immunol 31:706\u2013715","journal-title":"Parasite Immunol"},{"key":"1_CR12","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/NMD.0b013e3181f97c3d","volume":"198","author":"A Lovatt","year":"2010","unstructured":"Lovatt A, Mason O, Brett C, Peters E (2010) Psychotic-like experiences, appraisals, and trauma. J Nerv Ment Dis 198:813\u2013819","journal-title":"J Nerv Ment Dis"},{"key":"1_CR13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0165-0327(92)90042-5","volume":"26","author":"PJ Clayton","year":"1992","unstructured":"Clayton PJ, Guze SB, Cloninger CR, Martin RL (1992) Unipolar depression: diagnostic inconsistency and its implications. J Affect Disord 26:111\u2013116","journal-title":"J Affect Disord"},{"key":"1_CR14","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1176\/appi.ajp.2011.11010048","volume":"168","author":"EJ Bromet","year":"2011","unstructured":"Bromet EJ, Kotov R, Fochtmann LJ, Carlson GA, Tanenberg-Karant M, Ruggero C et al (2011) Diagnostic shifts during the decade following first admission for psychosis. Am J Psychiatry 168:1186\u20131194","journal-title":"Am J Psychiatry"},{"key":"1_CR15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/schbul\/18.2.159","volume":"18","author":"EF Torrey","year":"1992","unstructured":"Torrey EF (1992) Are we overestimating the genetic contribution to schizophrenia? Schizophr Bull 18:159\u2013170","journal-title":"Schizophr Bull"},{"key":"1_CR16","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/schbul\/18.2.171","volume":"18","author":"M McGue","year":"1992","unstructured":"McGue M (1992) When assessing twin concordance, use the probandwise not the pairwise rate. Schizophr Bull 18:171\u2013176","journal-title":"Schizophr Bull"},{"key":"1_CR17","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0006-3223(99)00289-9","volume":"47","author":"M Tsuang","year":"2000","unstructured":"Tsuang M (2000) Schizophrenia: genes and environment. Biol Psychiatry 47:210\u2013220","journal-title":"Biol Psychiatry"},{"key":"1_CR18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1079\/095442299108728947","volume":"12","author":"MJ Dauncey","year":"1999","unstructured":"Dauncey MJ, Bicknell RJ (1999) Nutrition and neurodevelopment: mechanisms of developmental dysfunction and disease in later life. Nutr Res Rev 12:231\u2013253","journal-title":"Nutr Res Rev"},{"key":"1_CR19","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.bbi.2009.02.001","volume":"23","author":"W Schlotz","year":"2009","unstructured":"Schlotz W, Phillips DI (2009) Fetal origins of mental health: evidence and mechanisms. Brain Behav Immun 23:905\u2013916","journal-title":"Brain Behav Immun"},{"key":"1_CR20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0893-133X(01)00396-7","volume":"27","author":"JI Koenig","year":"2002","unstructured":"Koenig JI, Kirkpatrick B, Lee P (2002) Glucocorticoid hormones and early brain development in schizophrenia. Neuropsychopharmacology 27:309\u2013318","journal-title":"Neuropsychopharmacology"},{"key":"1_CR21","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1176\/appi.ajp.160.2.284","volume":"160","author":"MC Ryan","year":"2003","unstructured":"Ryan MC, Collins P, Thakore JH (2003) Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160:284\u2013489","journal-title":"Am J Psychiatry"},{"key":"1_CR22","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1464-5491.2007.02092.x","volume":"24","author":"LM Spelman","year":"2007","unstructured":"Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH (2007) Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med 24:481\u2013445","journal-title":"Diabet Med"},{"key":"1_CR23","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/mp.2009.81","volume":"15","author":"PC Guest","year":"2010","unstructured":"Guest PC, Wang L, Harris LW, Burling K, Levin Y, Ernst A et al (2010) Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naive schizophrenia patients. Mol Psychiatry 15:118\u2013119","journal-title":"Mol Psychiatry"},{"key":"1_CR24","first-page":"450","volume":"10","author":"A Szulc","year":"2001","unstructured":"Szulc A, Gali\u0144ska B, Konarzewska B, Gudel-Trochimowicz I, Pop\u0142awska R (2001) Immunological marker activity in first episode schizophrenic patients. Pol Merkur Lekarski 10:450\u2013452","journal-title":"Pol Merkur Lekarski"},{"key":"1_CR25","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/schbul\/sbq062","volume":"38","author":"JA Van Venrooij","year":"2012","unstructured":"Van Venrooij JA, Fluitman SB, Lijmer JG, Kavelaars A, Heijnen CJ, Westenberg HG et al (2012) Impaired neuroendocrine and immune response to acute stress in medication-naive patients with a first episode of psychosis. Schizophr Bull 38:272\u2013279","journal-title":"Schizophr Bull"},{"key":"1_CR26","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/schbul\/sbu099","volume":"41","author":"DO Perkins","year":"2014","unstructured":"Perkins DO, Jeffries CD, Addington J, Bearden CE, Cadenhead KS, Cannon TD et al (2014) Towards a psychosis risk blood diagnostic for persons experiencing high-risk symptoms: preliminary results from the NAPLS project. Schizophr Bull 41:419\u2013428","journal-title":"Schizophr Bull"},{"key":"1_CR27","doi-asserted-by":"publisher","first-page":"e601","DOI":"10.1038\/tp.2015.91","volume":"5","author":"MK Chan","year":"2015","unstructured":"Chan MK, Krebs MO, Cox D, Guest PC, Yolken RH, Rahmoune H et al (2015) Development of a blood-based molecular biomarker test for identification of schizophrenia before disease onset. Transl Psychiatry 5:e601. doi: 10.1038\/tp.2015.91","journal-title":"Transl Psychiatry"},{"key":"1_CR28","first-page":"10","volume":"19","author":"M Agius","year":"2007","unstructured":"Agius M, Shah S, Ramkisson R, Murphy S, Zaman R (2007) Three year outcomes of an early intervention for psychosis service as compared with treatment as usual for first psychotic episodes in a standard community mental health team. Preliminary results. Psychiatr Danub 19:10\u201319","journal-title":"Psychiatr Danub"},{"key":"1_CR29","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1080\/08039480801984008","volume":"62","author":"RK Salokangas","year":"2008","unstructured":"Salokangas RK, McGlashan TH (2008) Early detection and intervention of psychosis. A review. Nord J Psychiatry 62:92\u2013105","journal-title":"Nord J Psychiatry"},{"key":"1_CR30","first-page":"689","volume":"51","author":"HL Yap","year":"2010","unstructured":"Yap HL (2010) Early psychosis intervention. Singapore Med J 51:689\u2013693","journal-title":"Singapore Med J"},{"issue":"Suppl 1","key":"1_CR31","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jad.2004.01.001","volume":"79","author":"P Thomas","year":"2004","unstructured":"Thomas P (2004) The many forms of bipolar disorder: a modern look at an old illness. J Affect Disord 79(Suppl 1):S3\u2013S8","journal-title":"J Affect Disord"},{"issue":"Suppl 14","key":"1_CR32","first-page":"5","volume":"62","author":"RM Hirschfeld","year":"2001","unstructured":"Hirschfeld RM (2001) Bipolar spectrum disorder: improving its recognition and diagnosis. J Clin Psychiatry 62(Suppl 14):5\u20139","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 5","key":"1_CR33","first-page":"5","volume":"66","author":"RM Post","year":"2005","unstructured":"Post RM (2005) The impact of bipolar depression. J Clin Psychiatry 66(Suppl 5):5\u201310","journal-title":"J Clin Psychiatry"},{"key":"1_CR34","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1183\/09031936.00033208","volume":"31","author":"N Kamel","year":"2008","unstructured":"Kamel N, Compton C, Middelveld R, Higenbottam T, Dahl\u00e9n SE (2008) The Innovative Medicines Initiative (IMI): a new opportunity for scientific collaboration between academia and industry at the European level. Eur Respir J 31:924\u2013926","journal-title":"Eur Respir J"},{"key":"1_CR35","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.drudis.2008.02.009","volume":"13","author":"AJ Hunter","year":"2008","unstructured":"Hunter AJ (2008) The innovative medicines initiative: a pre-competitive initiative to enhance the biomedical science base of Europe to expedite the development of new medicines for patients. Drug Discov Today 13:371\u2013373","journal-title":"Drug Discov Today"},{"key":"1_CR36","unstructured":"http:\/\/www.fda.gov\/MedicalDevices\/DeviceRegulationandGuidance\/IVDRegulatoryAssistance\/ucm124105.ht"},{"key":"1_CR37","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1373\/clinchem.2009.127514","volume":"56","author":"AA Ellington","year":"2010","unstructured":"Ellington AA, Kullo IJ, Bailey KR, Klee GG (2010) Antibody-based protein multiplex platforms: technical and operational challenges. Clin Chem 56:186\u2013193","journal-title":"Clin Chem"},{"key":"1_CR38","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/mp.2009.52","volume":"14","author":"J S\u00f6derlund","year":"2009","unstructured":"S\u00f6derlund J, Schr\u00f6der J, Nordin C, Samuelsson M, Walther-Jallow L, Karlsson H et al (2009) Activation of brain interleukin-1beta in schizophrenia. Mol Psychiatry 14:1069\u20131071","journal-title":"Mol Psychiatry"},{"key":"1_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000111642","volume":"14","author":"JE Merrill","year":"1992","unstructured":"Merrill JE (1992) Tumor necrosis factor alpha, interleukin 1 and related cytokines in brain development: normal and pathological. Dev Neurosci 14:1\u201310","journal-title":"Dev Neurosci"},{"key":"1_CR40","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/schbul\/sbn022","volume":"35","author":"U Meyer","year":"2009","unstructured":"Meyer U, Feldon J, Yee BK (2009) A review of the fetal brain cytokine imbalance hypothesis of schizophrenia. Schizophr Bull 35:959\u2013972","journal-title":"Schizophr Bull"},{"key":"1_CR41","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-244X-7-46","volume":"7","author":"P Saetre","year":"2007","unstructured":"Saetre P, Emilsson L, Axelsson E, Kreuger J, Lindholm E, Jazin E (2007) Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry 7:46","journal-title":"BMC Psychiatry"},{"key":"1_CR42","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3109\/15622975.2010.530690","volume":"12","author":"A Schmitt","year":"2011","unstructured":"Schmitt A, Leonardi-Essmann F, Durrenberger PF, Parlapani E, Schneider-Axmann T, Spanagel R et al (2011) Regulation of immune-modulatory genes in left superior temporal cortex of schizophrenia patients: a genome-wide microarray study. World J Biol Psychiatry 12:201\u2013215","journal-title":"World J Biol Psychiatry"},{"issue":"Suppl 2","key":"1_CR43","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0924-9338(10)71699-0","volume":"25","author":"AL Montejo","year":"2010","unstructured":"Montejo AL (2010) The need for routine physical health care in schizophrenia. Eur Psychiatry 25(Suppl 2):S3\u2013S5","journal-title":"Eur Psychiatry"},{"key":"1_CR44","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jpsychires.2012.03.019","volume":"46","author":"M Pedrini","year":"2012","unstructured":"Pedrini M, Massuda R, Fries GR, de Bittencourt Pasquali MA, Schnorr CE, Moreira JC et al (2012) Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. J Psychiatr Res 46:819\u2013824","journal-title":"J Psychiatr Res"},{"key":"1_CR45","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","volume":"70","author":"BJ Miller","year":"2011","unstructured":"Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B (2011) Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70:663\u2013671","journal-title":"Biol Psychiatry"},{"key":"1_CR46","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4137\/BMI.S4877","volume":"5","author":"E Schwarz","year":"2010","unstructured":"Schwarz E, Izmailov R, Spain M, Barnes A, Mapes JP, Guest PC et al (2010) Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark Insights 5:39\u201347","journal-title":"Biomark Insights"},{"key":"1_CR47","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/mp.2011.42","volume":"17","author":"E Schwarz","year":"2012","unstructured":"Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM et al (2012) Identification of a biological signature for schizophrenia in serum. Mol Psychiatry 17:494\u2013502","journal-title":"Mol Psychiatry"},{"key":"1_CR48","first-page":"1212","volume":"79","author":"E Sp\u00e4th-Schwalbe","year":"1994","unstructured":"Sp\u00e4th-Schwalbe E, Born J, Schrezenmeier H, Bornstein SR, Stromeyer P, Drechsler S et al (1994) Interleukin-6 stimulates the hypothalamus-pituitary-adrenocortical axis in man. J Clin Endocrinol Metab 79:1212\u20131214","journal-title":"J Clin Endocrinol Metab"},{"key":"1_CR49","first-page":"S23","volume":"29","author":"RH Straub","year":"2011","unstructured":"Straub RH, Buttgereit F, Cutolo M (2011) Alterations of the hypothalamic-pituitary adrenal axis in systemic immune diseases \u2013 a role for misguided energy regulation. Clin Exp Rheumatol 29:S23\u2013S31","journal-title":"Clin Exp Rheumatol"},{"key":"1_CR50","doi-asserted-by":"crossref","first-page":"445","DOI":"10.31887\/DCNS.2006.8.4\/jbremner","volume":"8","author":"JD Bremner","year":"2006","unstructured":"Bremner JD (2006) Traumatic stress: effects on the brain. Dialogues Clin Neurosci 8:445\u2013461","journal-title":"Dialogues Clin Neurosci"},{"key":"1_CR51","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000329846","volume":"95","author":"AT Spijker","year":"2012","unstructured":"Spijker AT, van Rossum EF (2012) Glucocorticoid sensitivity in mood disorders. Neuroendocrinology 95:179\u2013186","journal-title":"Neuroendocrinology"},{"key":"1_CR52","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1055\/s-2004-832682","volume":"37","author":"N M\u00fcller","year":"2004","unstructured":"M\u00fcller N, Riedel M, Schwarz MJ (2004) Psychotropic effects of COX-2 inhibitors \u2013 a possible new approach for the treatment of psychiatric disorders. Pharmacopsychiatry 37:266\u2013269","journal-title":"Pharmacopsychiatry"},{"key":"1_CR53","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.schres.2006.11.016","volume":"90","author":"S Akhondzadeh","year":"2007","unstructured":"Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH et al (2007) Celecoxib as adjunctive therapy in schizophrenia: a doubleblind, randomized and placebo-controlled trial. Schizophr Res 90:179\u2013185","journal-title":"Schizophr Res"},{"key":"1_CR54","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.schres.2010.04.015","volume":"121","author":"N M\u00fcller","year":"2010","unstructured":"M\u00fcller N, Krause D, Dehning S, Musil R, Schennach-Wolff R, Obermeier M et al (2010) Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebocontrolled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res 121:118\u2013124","journal-title":"Schizophr Res"},{"key":"1_CR55","doi-asserted-by":"crossref","first-page":"520","DOI":"10.4088\/JCP.09m05117yel","volume":"71","author":"W Laan","year":"2010","unstructured":"Laan W, Grobbee DE, Selten JP, Heijnen CJ, Kahn RS, Burger H (2010) Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 71:520\u2013527","journal-title":"J Clin Psychiatry"},{"key":"1_CR56","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.4088\/JCP.v65n1007","volume":"65","author":"B Arranz","year":"2004","unstructured":"Arranz B, Rosel P, Ramirez N, Duenas R, Fernandez P, Sanchez JM et al (2004) Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first episode schizophrenia patients. J Clin Psychiatry 65:1335\u20131342","journal-title":"J Clin Psychiatry"},{"key":"1_CR57","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1177\/070674370605100608","volume":"51","author":"TA Cohn","year":"2006","unstructured":"Cohn TA, Remington G, Zipursky RB, Azad A, Connolly P, Wolever TM (2006) Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Can J Psychiatry 51:382\u2013386","journal-title":"Can J Psychiatry"},{"key":"1_CR58","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/mp.2009.87","volume":"15","author":"J Steiner","year":"2010","unstructured":"Steiner J, Walter M, Guest P, Myint AM, Schiltz K, Panteli B et al (2010) Elevated S100B levels in schizophrenia are associated with insulin resistance. Mol Psychiatry 15:3\u20134","journal-title":"Mol Psychiatry"},{"key":"1_CR59","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.psyneuen.2010.12.018","volume":"36","author":"PC Guest","year":"2011","unstructured":"Guest PC, Schwarz E, Krishnamurthy D, Harris LW, Leweke FM, Rothermundt M et al (2011) Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology 36:1092\u20131096","journal-title":"Psychoneuroendocrinology"},{"key":"1_CR60","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1126\/science.1142179","volume":"317","author":"A Taguchi","year":"2007","unstructured":"Taguchi A, Wartschow LM, White MF (2007) Brain IRS2 signaling coordinates life span and nutrient homeostasis. Science 317:369\u2013372","journal-title":"Science"},{"issue":"Suppl 1","key":"1_CR61","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.neurobiolaging.2005.09.018","volume":"26","author":"A Convit","year":"2005","unstructured":"Convit A (2005) Links between cognitive impairment in insulin resistance: an explanatory model. Neurobiol Aging 26(Suppl 1):31\u201335","journal-title":"Neurobiol Aging"},{"key":"1_CR62","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2174\/156720507780362137","volume":"4","author":"S Craft","year":"2007","unstructured":"Craft S (2007) Insulin resistance and Alzheimer\u2019s disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res 4:147\u2013152","journal-title":"Curr Alzheimer Res"},{"key":"1_CR63","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.physbeh.2006.03.027","volume":"88","author":"NT Bello","year":"2006","unstructured":"Bello NT, Hajnal A (2006) Alterations in blood glucose levels under hyperinsulinemia affect accumbens dopamine. Physiol Behav 88:138\u2013145","journal-title":"Physiol Behav"},{"key":"1_CR64","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0028-3908(03)00081-9","volume":"44","author":"D O\u2019Malley","year":"2003","unstructured":"O\u2019Malley D, Shanley LJ, Harvey J (2003) Insulin inhibits rat hippocampal neurones via activation of ATP-sensitive K+ and large conductance Ca2+\u2212activated K+ channels. Neuropharmacology 44:855\u2013863","journal-title":"Neuropharmacology"},{"key":"1_CR65","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.schres.2011.11.035","volume":"135","author":"CM Corcoran","year":"2012","unstructured":"Corcoran CM, Smith C, McLaughlin D, Auther A, Malaspina D, Cornblatt B (2012) HPA axis function and symptoms in adolescents at clinical high risk for schizophrenia. Schizophr Res 135:170\u2013174","journal-title":"Schizophr Res"},{"key":"1_CR66","first-page":"17","volume":"110","author":"LN Gorobets","year":"2010","unstructured":"Gorobets LN, Matrosova MI (2010) Specialties of prolactin secretion and peripheral reproductive sex hormones in patients with of first episode of schizophrenia. Zh Nevrol Psikhiatr Im S S Korsakova 110:17\u201322","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"1_CR67","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/1756-0500-5-169","volume":"5","author":"MO Akiibinu","year":"2012","unstructured":"Akiibinu MO, Ogundahunsi OA, Ogunyemi EO (2012) Inter-relationship of plasma markers of oxidative stress and thyroid hormones in schizophrenics. BMC Res Notes 5:169","journal-title":"BMC Res Notes"},{"key":"1_CR68","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.tem.2006.02.005","volume":"17","author":"N Ben-Jonathan","year":"2006","unstructured":"Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR (2006) Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab 17:110\u2013116","journal-title":"Trends Endocrinol Metab"},{"key":"1_CR69","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1210\/endo-99-3-720","volume":"99","author":"GS Tannenbaum","year":"1976","unstructured":"Tannenbaum GS, Martin JB, Colle E (1976) Ultradian growth hormone rhythm in the rat: effects of feeding, hyperglycemia, and insulin-induced hypoglycemia. Endocrinology 99:720\u2013727","journal-title":"Endocrinology"},{"key":"1_CR70","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0920-9964(01)00326-7","volume":"59","author":"HY Meltzer","year":"2003","unstructured":"Meltzer HY, Perry E, Jayathilake K (2003) Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr Res 59:19\u201327","journal-title":"Schizophr Res"},{"key":"1_CR71","doi-asserted-by":"crossref","first-page":"601","DOI":"10.4158\/EP.13.6.601","volume":"13","author":"G Bahtiyar","year":"2007","unstructured":"Bahtiyar G, Weiss K, Sacerdote AS (2007) Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone. Endocr Pract 13:601\u2013608","journal-title":"Endocr Pract"},{"key":"1_CR72","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.neurobiolaging.2009.10.009","volume":"32","author":"T Sato","year":"2011","unstructured":"Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T (2011) Efficacy of PPARgamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 32:1626\u20131633","journal-title":"Neurobiol Aging"},{"key":"1_CR73","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.schres.2005.07.029","volume":"79","author":"T Nachshoni","year":"2005","unstructured":"Nachshoni T, Ebert T, Abramovitch Y, Assael-Amir M, Kotler M, Maayan R et al (2005) Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Schizophr Res 79:251\u2013256","journal-title":"Schizophr Res"},{"key":"1_CR74","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.4088\/JCP.10m06610","volume":"72","author":"J Usall","year":"2011","unstructured":"Usall J, Huerta-Ramos E, Iniesta R, Cobo J, Araya S, Roca M et al (2011) Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 72:1552\u20131557","journal-title":"J Clin Psychiatry"},{"key":"1_CR75","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/S0140-6736(00)02221-2","volume":"355","author":"MJ Arranz","year":"2000","unstructured":"Arranz MJ, Munro J, Birkett J, Bolonna A, Mancama D, Sodhi M et al (2000) Pharmacogenetic prediction of clozapine response. Lancet 355:1615\u20131616","journal-title":"Lancet"},{"key":"1_CR76","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1517\/17425255.2011.532787","volume":"7","author":"JP Zhang","year":"2011","unstructured":"Zhang JP, Malhotra AK (2011) Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol 7:9\u201337","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1_CR77","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.jpsychires.2008.11.001","volume":"43","author":"S Gebhardt","year":"2009","unstructured":"Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M, Gebhardt N, Remschmidt H, Krieg JC et al (2009) Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. J Psychiatr Res 43:620\u2013626. doi: 10.1016\/j.jpsychires.2008.11.001 . Epub 2008 Dec 24","journal-title":"J Psychiatr Res"},{"key":"1_CR78","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/JCP.0000000000000476","volume":"36","author":"SL Lau","year":"2016","unstructured":"Lau SL, Muir C, Assur Y, Beach R, Tran B, Bartrop R et al (2016) Predicting weight gain in patients treated with clozapine: the role of sex, body mass index, and smoking. J Clin Psychopharmacol 36:120\u2013124","journal-title":"J Clin Psychopharmacol"},{"issue":"9","key":"1_CR79","first-page":"17","volume":"2012","author":"A Shrivastava","year":"2012","unstructured":"Shrivastava A, Johnston M, Bureau Y, Shah N (2012) Baseline serum prolactin in drug naive, first-episode schizophrenia and outcome at five years: is it a predictive factor? Innov Clin Neurosci 2012(9):17\u201321","journal-title":"Innov Clin Neurosci"},{"key":"1_CR80","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1038\/tp.2012.3","volume":"2","author":"E Schwarz","year":"2012","unstructured":"Schwarz E, Guest PC, Steiner J, Bogerts B, Bahn S (2012) Identification of blood based molecular signatures for prediction of response and relapse in schizophrenia patients. Transl Psychiatry 2:e82","journal-title":"Transl Psychiatry"},{"key":"1_CR81","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3109\/15622975.2013.817685","volume":"16","author":"E Schwarz","year":"2015","unstructured":"Schwarz E, Steiner J, Guest PC, Bogerts B, Bahn S (2015) Investigation of molecular serum profiles associated with predisposition to antipsychotic-induced weight gain. World J Biol Psychiatry 16:22\u201330","journal-title":"World J Biol Psychiatry"},{"key":"1_CR82","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.bbi.2015.10.019","volume":"52","author":"J Tomasik","year":"2016","unstructured":"Tomasik J, Schwarz E, Lago SG, Rothermundt M, Leweke FM, van Beveren NJ et al (2016) Pretreatment levels of the fatty acid handling proteins H-FABP and CD36 predict response to olanzapine in recent-onset schizophrenia patients. Brain Behav Immun 52:178\u2013186","journal-title":"Brain Behav Immun"},{"issue":"2","key":"1_CR83","doi-asserted-by":"crossref","first-page":"e9166","DOI":"10.1371\/journal.pone.0009166","volume":"5","author":"E Domenici","year":"2010","unstructured":"Domenici E, Will\u00e9 DR, Tozzi F, Prokopenko I, Miller S, McKeown A et al (2010) Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One 5(2):e9166","journal-title":"PLoS One"},{"key":"1_CR84","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4049\/jimmunol.103.1.129","volume":"103","author":"SE Salmon","year":"1969","unstructured":"Salmon SE, Mackey G, Fudenberg HH (1969) \u201cSandwich\u201d solid phase radioimmunoassay for the quantitative deterimination of human immunoglobulins. J Immunol 103:129\u2013137","journal-title":"J Immunol"},{"key":"1_CR85","doi-asserted-by":"crossref","first-page":"665","DOI":"10.4049\/jimmunol.104.3.665","volume":"104","author":"SE Salmon","year":"1970","unstructured":"Salmon SE, Smith BA (1970) Sandwich solid phase radioimmunoassays for the characterization of human immunoglobulins synthesized in vitro. J Immunol 104:665\u2013672","journal-title":"J Immunol"},{"key":"1_CR86","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1039\/C1LC20693A","volume":"12","author":"S Schumacher","year":"2012","unstructured":"Schumacher S, Nestler J, Otto T, Wegener M, Ehrentreich-F\u00f6rster E, Michel D et al (2012) Highly-integrated lab-on-chip system for point-of-care multiparameter analysis. Lab Chip 12:464\u2013473","journal-title":"Lab Chip"},{"key":"1_CR87","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1089\/tmj.2008.0099","volume":"15","author":"S Krishna","year":"2009","unstructured":"Krishna S, Boren SA, Balas EA (2009) Healthcare via cell phones: a systematic review. Telemed J E Health 15:231\u2013240","journal-title":"Telemed J E Health"},{"key":"1_CR88","doi-asserted-by":"crossref","first-page":"7857","DOI":"10.1021\/acsnano.5b03203","volume":"9","author":"B Berg","year":"2015","unstructured":"Berg B, Cortazar B, Tseng D, Ozkan H, Feng S, Wei Q et al (2015) Cellphone-based hand-held micro-plate reader for point-of-care testing of enzyme-linked immunosorbent assays. ACS Nano 9:7857\u20137866","journal-title":"ACS Nano"}],"container-title":["Advances in Experimental Medicine and Biology","Proteomic Methods in Neuropsychiatric Research"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-52479-5_1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T21:52:00Z","timestamp":1692741120000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-319-52479-5_1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9783319524788","9783319524795"],"references-count":88,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-52479-5_1","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}